Evaluation of immune infiltrate according to the HER2 status in colorectal cancer.
Fiche publication
Date publication
octobre 2023
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Pr GHIRINGHELLI François, Mr MONNIEN Franck, Dr VUITTON Lucine, Dr DERANGERE Valentin, Dr LAKKIS Zaher, Pr BIBEAU Frédéric , Dr MOLIMARD Chloé
Tous les auteurs :
Molimard C, Dor F, Overs A, Monnien F, Gessain G, Kedochim L, D'Angelo F, Abad M, Heberle M, Derangère V, Ghiringhelli F, Vuitton L, Valmary-Degano S, Borg C, Lakkis Z, Bibeau F
Lien Pubmed
Résumé
In colorectal cancer (CRC), HER2 targeting is a promising treatment and immune infiltrate is an important area of research and strategy. Data regarding HER2 status and immune infiltrate are lacking. The aim of this study was to compare the immune infiltrate between HER2 amplified and non-amplified categories in proficient MisMatchRepair (pMMR)/microsatellite stable (MSS) CRC.
Mots clés
Colorectal cancer, HER2, Immune infiltrate, QuPath software
Référence
Dig Liver Dis. 2023 10 14;: